Inï¿½silico analysis identifies CRISP3 as a potential peripheral blood biomarker for multiple myeloma: From data modeling to validation with RT-PCR

Dong, Liubing; Miao, Ran; Huang, Xiaoxi; Wang, Ying

doi:10.3892/ol.2018.7969

Cited by 7 publications

(5 citation statements)

References 35 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously described as upregulated as part of a 7-gene predictive signature of early primary prefibrotic myelofibrosis (prePMF) [ 18 ]. It has also been identified as a potential PB biomarker for multiple myeloma [ 19 ]. Its role in MPNs remains unclear.…”

Section: Resultsmentioning

confidence: 99%

Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations

Guijarro-Hernández,

Vizmanos

2023

BMC Genom Data

View full text Add to dashboard Cite

Background Essential thrombocythemia (ET) is one of the most common types of Ph-negative myeloproliferative neoplasms, an infrequent group of blood cancers that arise from a CD34 + hematopoietic stem cell (HSC) in the bone marrow (BM) primarily due to driver mutations in JAK2, CALR or MPL. These aberrations result in an overproduction of mature myeloid cells in peripheral blood (PB). To date, no targeted therapies have been approved for ET patients, so the study of the molecular mechanisms behind the disease and the identification of new therapeutic targets may be of interest. For this reason, in this study, we have compared the transcriptomic profile of undifferentiated CD34 + cells and mature myeloid cells from ET patients (CALR and JAK2-mutated) and healthy donors deposited in publicly available databases. The study of the similarities and differences between these samples might help to better understand the molecular mechanisms behind the disease according to the degree of maturation of the malignant clone and the type of mutation and ultimately help identify new therapeutic targets for these patients. Results The results show that most of the altered hallmarks in neutrophils were also found in CD34 + cells. However, only a few genes showed a similar aberrant expression pattern in both types of cells. We have identified a signature of six genes common to patients with CALR and JAK2 mutations (BPI, CRISP3, LTF, MMP8, and PTGS1 upregulated, and PBXIP1 downregulated), a different signature of seven genes for patients with CALR mutations (BMP6, CEACAM8, ITK, LCN2, and PRG2 upregulated, and MAN1A1 and MME downregulated) and a signature of 13 genes for patients with JAK2 mutations (ARG1, CAST, CD177, CLEC5A, DAPP1, EPS15, IL18RAP, OLFM4, OLR1, RIOK3, SELP, and THBS1 upregulated, and IGHM downregulated). Conclusions Our results highlight transcriptomic similarities and differences in ET patients according to the degree of maturation of the malignant clone and the type of mutation. The genes and processes altered in both CD34 + cells and mature neutrophils may reveal altered sustained processes that could be studied as future therapeutic targets for ET patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations

Guijarro-Hernández,

Vizmanos

2023

BMC Genom Data

View full text Add to dashboard Cite

show abstract

“…Human CRISP3 is located on human chromosome 6 and is the third member of the cysteine rich secretory protein family and is widely distributed in human tissues. It is detected in human body fluid secretion including sweat, plasma, prostate, pancreas and salivary glands [20]. The study found that CRISP3 is low expressed in colon, thymus, ovary and epididymis tissues, but its specific function has not been clearly studied [21].…”

Section: Discussionmentioning

confidence: 98%

Diagnostic Value of SMARCE1 and CRISP3 Combined with Tumor Markers in Cervical Cancer

He¹,

Wang²,

Zhang³

2023

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

Background: To investigate the diagnostic value of SMARCE1, cysteine-rich secreted protein 3 (CRISP3) combined with tumor markers in the diagnosis of cervical cancer. Methods: A total of 80 patients with cervical lesions who were diagnosed and treated in our hospital from January 2020 to March 2022 were selected and divided into control group (chronic cervicitis, n = 30) and observation group (cervical cancer, n = 50). Immunohistochemistry was used to detect the expression levels of SMARCE1 and CRISP3 in cervical tissue of the two groups of subjects, and the relationship between the expression of SMARCE1 and CRISP3 in cervical cancer tissue and the clinicopathological data of the patients was analyzed. In addition, the serum tumor marker levels of the two groups of subjects were detected, and the diagnostic value of SMARCE1 and CRISP3 combined with tumor markers in cervical cancer was analyzed. The female sexual function index (FSFI) and the functional assessment of cancer therapy-general (FACT-G) score were used to evaluate female sexual function and quality of life. Results: The positive expression rates of SMARCE1 and CRISP3 in the observation group were significantly higher than those in the control group (p < 0.05). There was no significant difference in the positive expression of SMARCE1 and CRISP3 among cervical cancer patients with age, lymph node metastasis and tumor node metastasis (TNM) classification stage (p > 0.05), and the lower the degree of tumor differentiation, the higher the positive expression rate of SMARCE1 and CRISP3 proteins (p < 0.05). The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125 and CA153 in the observation group were significantly higher than those in the control group (p < 0.05). The results of the receiver operating characteristic (ROC) curve analysis showed that the area under curve (AUC) values of SMARCE1, SMARCE1 + tumor markers, CRISP3, CRISP3 + tumor markers, SMARCE1, CRISP3 combined with tumor markers for the diagnosis of cervical cancer were 0.760, 0.851, 0.739, 0.810, and 0.944, respectively. Conclusions: SMARCE1 and CRISP3 are expressed in patients with cervical cancer, and CEA, CA125, and CA153 are expressed at high levels in the serum of patients with cervical cancer. The combined detection of SMARCE1 and CRISP3 combined with tumor markers has high clinical diagnostic value for cervical cancer.

show abstract

“…CONOR and preprocessCore in the R software package were used to combine the gene expression estimates from different studies [ 15 , 16 ]. During the data-merging process, the Log2-transformed raw intensity estimates were transformed by iterative clustering until convergence to a minimum sum of the Euclidean distance, which has been proven to be an effective means to remove systematic differences between studies while preserving the completeness of the biological information [ 17 , 18 ].…”

Section: Methodsmentioning

confidence: 99%

Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling

Dong

Xiang

et al. 2020

BMC Cancer

Self Cite

View full text Add to dashboard Cite

Background Idiopathic pulmonary fibrosis (IPF) is associated with an increased risk for lung cancer, but the underlying mechanisms driving malignant transformation remain largely unknown. This study aimed to identify differentially expressed genes (DEGs) distinguishing IPF and lung cancer from healthy individuals and common genes driving the transformation from healthy to IPF and lung cancer. Methods The gene expression data for IPF and non-small cell lung cancer (NSCLC) were retrieved from the Gene Expression Omnibus (GEO) database. The DEG signatures were identified via unsupervised two-way clustering (TWC) analysis, supervised support vector machine analysis, dimensional reduction, and mutual exclusivity analysis. Gene enrichment and pathway analyses were performed to identify common signaling pathways. The most significant signature genes in common among IPF and lung cancer were further verified by immunohistochemistry. Results The gene expression data from GSE24206 and GSE18842 were merged into a super array dataset comprising 86 patients with lung disorders (17 IPF and 46 NSCLC) and 51 healthy controls and measuring 23,494 unique genes. Seventy-nine signature DEGs were found among IPF and NSCLC. The peroxisome proliferator-activated receptor (PPAR) signaling pathway was the most enriched pathway associated with lung disorders, and matrix metalloproteinase-1 (MMP-1) in this pathway was mutually exclusive with several genes in IPF and NSCLC. Subsequent immunohistochemical analysis verified enhanced MMP1 expression in NSCLC associated with IPF. Conclusions For the first time, we defined common signature genes for IPF and NSCLC. The mutually exclusive sets of genes were potential drivers for IPF and NSCLC.

show abstract

Inï¿½silico analysis identifies CRISP3 as a potential peripheral blood biomarker for multiple myeloma: From data modeling to validation with RT-PCR

Cited by 7 publications

References 35 publications

Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations

Transcriptomic comparison of bone marrow CD34 + cells and peripheral blood neutrophils from ET patients with JAK2 or CALR mutations

Diagnostic Value of SMARCE1 and CRISP3 Combined with Tumor Markers in Cervical Cancer

Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling

Contact Info

Product

Resources

About